Ignite Creation Date:
2025-12-24 @ 4:14 PM
Ignite Modification Date:
2025-12-24 @ 4:14 PM
Study NCT ID:
NCT04476966
Status:
COMPLETED
Last Update Posted:
2020-07-21
First Post:
2020-07-15
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)
Sponsor:
Genuine Research Center, Egypt
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-01-20
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-05-11
Completion Date Type:
ACTUAL
First Submit Date:
2020-07-15
First Submit QC Date:
None
Study First Post Date:
2020-07-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-07-20
Last Update Post Date:
2020-07-21
Last Update Post Date Type:
ACTUAL